Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-Induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Monocenter, Randomized, Stratified, Double-Blinded, Placebo-Controlled Phase IV Study

Trial Profile

Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-Induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Monocenter, Randomized, Stratified, Double-Blinded, Placebo-Controlled Phase IV Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms LeLeDys
  • Most Recent Events

    • 24 Mar 2011 Status changed from recruiting to completed.
    • 16 Jan 2009 Planned number of patients changed from 44 to 34 as reported by ClinicalTrials.gov.
    • 16 Jan 2009 Planned end date changed from 1 Aug 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top